Karyopharm Therapeutics Inc. (KPTIQ) SEC filings

KPTIQPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30

Share price

Not available yet

Price, market cap and P/E appear here once daily prices are connected.

SEC filings

40 of Karyopharm Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 4, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 3, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 2, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	8-K	Oct 13, 2026	Oct 14, 2026	SEC EDGAR
Current report	8-K	Sep 17, 2026	Sep 18, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Aug 31, 2026	Aug 31, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 30, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 13, 2026	Jul 17, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 28, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 13, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Mar 27, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Current report	8-K	Feb 27, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 19, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 13, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Proxy statement	DEF 14A	Feb 18, 2026	Jan 9, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 10, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Oct 7, 2025	Oct 8, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 11, 2025	Jul 11, 2025	SEC EDGAR
Current report	8-K	May 28, 2025	May 29, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 28, 2025	Apr 14, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 24, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 19, 2025	SEC EDGAR
Current report	8-K	Feb 19, 2025	Feb 19, 2025	SEC EDGAR
Current report	8-K	Jan 27, 2025	Jan 31, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Karyopharm Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Feb 26, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KPTIQ.

Compare: KPTIQ vs LGND · KPTIQ vs AMRN · KPTIQ vs IDYA · KPTIQ vs TNGX · KPTIQ vs AKBA

Revenue growth6.8% · median -17.4%

Operating margin-56.2% · median -17.0%

Net margin-153.3% · median -16.7%

Company	Revenue	Growth
LGND	$253.83M	+1.0%
IDYA	$234.13M	–
AKBA	$197.20M	-12.4%
AMRN	$176.11M	-22.3%
KPTIQ	$146.62M	+6.8%
TNGX	$0	-100.0%

Company

Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 228
Auditor: Ernst & Young LLP
SEC CIK: 1503802

Advertisement
300 × 250

See a number that looks wrong?